Request Demo

Last update 20 Feb 2025

Biotin

Last update 20 Feb 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy.

Drug Type

Small molecule drug

Synonyms

(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid

+ [16]

Target

ABCD1

Mechanism

ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal DiseasesNervous System Diseases+ [2]

Active Indication

Diabetes MellitusEczemaAlzheimer Disease+ [2]

Inactive Indication

Amyotrophic Lateral SclerosisCharcot-Marie-Tooth Disease, Type IaCharcot-Marie-Tooth Disease, Type Ib+ [7]

Originator Organization-

Active Organization

Harvard Medical School

Washington & Jefferson CollegeCiberer

+ [1]

Inactive Organization

MedDay Pharmaceuticals SAS

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (US)

Structure/Sequence

Molecular FormulaC10H16N2O3S

InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N

CAS Registry58-85-5

Clinical Trials associated with Biotin

TCTR20240411004

/ CompletedPhase 2IIT

An Experimental Study on the effect of biotin on Measurement of FT3, FT4 and TSH in healthy adults

Start Date22 Aug 2023

Sponsor / Collaborator-

CTRI/2023/07/055359

/ CompletedNot Applicable

A Randomized Double-Blind Placebo-Controlled Safety and Efficacy Study of Plant Based Biotin and Plant Based Biotin with Silica in Healthy Adult Human Subjects with complaints of Hair Fall Thin Dry & Brittle Hair and Dry Skin - NIL

Start Date01 Aug 2023

Sponsor / Collaborator-

CTRI/2023/07/055057

/ CompletedPhase 3

An Open Label, Prospective, Non-Comparative, Single Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of H-Vit Hair Serum of Systopic Laboratories Pvt. Ltd. in Hair Fall Control, Hair Growth Potential and Improvement in Hair Health in Adult Volunteers - NIL

Start Date31 Jul 2023

Sponsor / Collaborator

Systopic Laboratories Private Limited

[+1]

100 Clinical Results associated with Biotin

100 Translational Medicine associated with Biotin

100 Patents (Medical) associated with Biotin

29,687

Literatures (Medical) associated with Biotin

01 May 2025·BIOMATERIALS

Myocardial delivery of miR30d with peptide-functionalized milk-derived extracellular vesicles for targeted treatment of hypertrophic heart failure

Article

Author: Yi, Huaxi ; Yin, Wenchao ; Xu, Jiarun ; Zhang, Yameng ; Lai, Fengling ; Wang, Qiyue ; Zhang, Sitong ; Yin, Jie ; Wang, Jiong-Wei ; Wang, Zhaoyang ; Huang, Rong ; Wei, Guoyue ; Tong, Lingjun ; Xu, Tao ; Storm, Gert

miR30d has been shown to reverse cardiac hypertrophy. However, effective delivery of miR30d to the heart is challenging. Here, we engineered milk-derived extracellular vesicles (mEVs) by surface functionalization with an ischemic myocardium-targeting peptide (IMTP) and encapsulated miR30d to develop a formulation, the miR30d-mEVs^IMTP, enabling targeted delivery of miR30d to the injured heart. In vitro, the miR30d-mEVs^IMTP can be effectively internalized by hypoxia-induced H9C2 cells via the endo-lysosomal pathway. In the isoproterenol (ISO)-induced cardiac hypertrophy mice, more miR30d-mEVs^IMTP accumulated in cardiac tissue than miR30d-mEVs following intravenous administration. As a result, miR30d-mEVs^IMTP alleviated cardiac hypertrophy and rescued cardiac function in three murine models of hypertrophic heart failure. Mechanistically, we identified GRK5 as an unprecedented target of miR30d in cardiac hypertrophy. Taken together, our findings demonstrate that mEVs conjugated with IMTP effectively deliver miR30d to the pathological heart and thereby ameliorating cardiac hypertrophy and dysfunction via targeting GRK5-mediated signaling pathways.

01 Apr 2025·JOURNAL OF COLLOID AND INTERFACE SCIENCE

DNA Tetrahedron-enhanced single-particle counting integrated with cascaded CRISPR Program for ultrasensitive dual RNAs logic sensing

Article

Author: Ying, Binwu ; Wu, Yao ; Jiang, Yujia ; Chen, Hao ; Lei, Jiahui ; Liu, Tangyuheng ; Lan, Fang ; Zhan, Xiaohui

CRISPR-Cas-based technology, emerging as a leading platform for molecular assays, has been extensively researched and applied in bioanalysis. However, achieving simultaneous and highly sensitive detection of multiple nucleic acid targets remains a significant challenge for most current CRISPR-Cas systems. Herein, a CRISPR Cas12a based calibratable single particle counting-mediated biosensor was constructed for dual RNAs logic and ultra-sensitive detection in one tube based on DNA Tetrahedron (DTN)-interface supported fluorescent particle probes coupled with a novel synergistic cascaded strategy between CRISPR Cas13a system and strand displacement amplification (SDA). As expected, our platform enables dual RNA molecules intelligent detection using only one crRNA of Cas13a, achieving a sensitivity enhancement of three orders of magnitude assisted with multiple signal amplification and accurate fluorescence particle counting with DTN mediated nano-biointerface enhancement, compared to traditional bulk Cas13a assays. Moreover, the effectiveness and universality of our strategy are experimentally investigated and demonstrated through the detection of mRNAs (cervical cancer swab clinical samples and cultured cancer cells) and bacterial 16s rRNAs. This work not only proposes a highly promising avenue for designing CRISPR-based multiplex detection systems that excel in ultra-sensitivity, specificity, and clinical molecular diagnostics, but also provide new insights into the potential applications of nanotechnology in molecular diagnostics, functional surface engineering, and interface-mediated bioreactions.

01 Apr 2025·TALANTA

Tetrahedral DNA nanostructures-assisted electrochemical assay for detecting circulating tumor DNA by combining a masking tactic with 3D-hybridization chain reactions

Article

Author: Qiu, Yulou ; Wang, Jianping ; Duan, Xueyuan ; Hao, Jicong ; Ye, Zihong ; Qin, Weiwei ; Yu, Xiaoping ; ShenTu, Xuping

Circulating tumor DNA (ctDNA) is a remarkable noninvasive tumor marker that plays a crucial role in tumor diagnosis, prognosis and treatment. However, detecting low-abundance ctDNA from a substantial amount of nucleic acids originating from healthy cells is challenging. Herein, we proposed a tetrahedral DNA nanostructures (TDNs)-assisted electrochemical biosensor for ctDNA detection. This biosensor combines a masking tactic with 3D-hybridization chain reactions. Masking hairpins (MHs) were initially introduced to prevent interference from wild-type (WT) DNA. Then, the initiator sequence was transferred to the electrode surface modified with TDNs by the target ctDNA. The initiator sequence triggers the 3D self-assembly of hairpin strands, leading to the formation of DNA networks or even DNA hydrogels (long reaction time). This process generates numerous evenly distributed biotin molecules that can bind to streptavidin peroxidase to considerably amplify the signal. This method exhibits high sensitivity (the minimum concentration for detecting ctDNA is 1 aM, which corresponds to 60 ctDNA molecules in 100 μl sample) and excellent specificity (single mismatch). More importantly, this high-performance sensor can detect ctDNA with other mutation sites and their mixtures by modifying the corresponding capture probes on the TDNs. Furthermore, this ultrasensitive sensor effectively detects target ctDNA (0.001 %) at high levels of WT DNA and in complex matrices such as serum. These findings suggest that the sensor has promising potential as a noninvasive tool for early tumor diagnosis.

News (Medical) associated with Biotin

17 Jun 2024

·www.sciencedaily.com

Treating the gut-brain connection with B vitamins to treat Parkinson's Disease

A study has revealed a link between gut microbiota and Parkinson's disease. The researchers discovered a decrease in bacterial genes related to the synthesis of vitamins B2 and B7. The lack of these genes was associated with reduced intestinal short-chain fatty acids and polyamines, agents that maintain the intestinal barrier and prevent the leakage of toxins into the blood that can then access the brain. Using B vitamin therapy to address these deficiencies may restore the barrier and treat Parkinson's disease. A study led by Nagoya University Graduate School of Medicine in Japan has revealed a link between gut microbiota and Parkinson's disease (PD). The researchers found a reduction in the gut bacteria of genes responsible for synthesizing the essential B vitamins B2 and B7. They also identified a relationship between the lack of these genes and low levels of agents that help maintain the integrity of the intestinal barrier. This barrier prevents toxins from entering the bloodstream, which causes the inflammation seen in PD. Their findings, published in npj Parkinson's Disease, suggest that treatment with B vitamins to address these deficiencies can be used to treat PD. PD is characterized by a variety of physical symptoms that hinder daily activities and mobility, such as shaking, slow movement, stiffness, and balance problems. While the frequency of PD may vary between different populations, it is estimated to affect approximately 1-2% of individuals aged 55 years or older. Various physiological processes are heavily influenced by the microorganisms found in the gut, which are collectively known as gut microbiota. In ideal conditions, gut microbiota produce SCFAs and polyamines, which maintain the intestinal barrier that prevents toxins entering the bloodstream. Toxins in the blood can be carried to the brain where they cause inflammation and affect neurotransmission processes that are critical for maintaining mental health. To better understand the relationship between the microbial characteristics of the gut in PD, Hiroshi Nishiwaki and Jun Ueyama from the Nagoya University Graduate School of Medicine conducted a metanalysis of stool samples from patients with PD from Japan, the United States, Germany, China, and Taiwan. They used shotgun sequencing, a technique that sequences all genetic material in a sample. This is an invaluable tool because it offers researchers a better understanding of the microbial community and genetic makeup of the sample. They observed a decrease in the bacterial genes responsible for the synthesizing of riboflavin (vitamin B2) and biotin (vitamin B7) in patients diagnosed with PD. Riboflavin and biotin, derived from both food and gut microbiota, have anti-inflammatory properties, which may counteract the neuroinflammation seen in diseases like PD. B vitamins play crucial roles in the metabolic processes that influence the production and functions of short-chain fatty acids (SCFAs) and polyamines, two agents that help maintain the integrity of the intestinal barrier, preventing toxins entering the bloodstream. An examination of fecal metabolites revealed decreases of both in patients with PD. The findings indicate a potential explanation for the progression of PD. "Deficiencies in polyamines and SCFAs could lead to thinning of the intestinal mucus layer, increasing intestinal permeability, both of which have been observed in PD," Nishiwaki explained. "This higher permeability exposes nerves to toxins, contributing to abnormal aggregation of alpha-synuclein, activating the immune cells in the brain, and leading to long-term inflammation." He added, "Supplementation therapy targeting riboflavin and biotin holds promise as a potential therapeutic avenue for alleviating PD symptoms and slowing disease progression." The results of the study highlight the importance of understanding the complex relationship among gut microbiota, metabolic pathways, and neurodegeneration. In the coming years, therapy could potentially be customized based on the unique microbiome pro each patient. By altering bacterial levels in the microbiome, doctors can potentially delay the onset of symptoms associated with diseases like PD. "We could perform gut microbiota analysis on patients or conduct fecal metabolite analysis," Nishiwaki said. "Using these findings, we could identify individuals with specific deficiencies and administer oral riboflavin and biotin supplements to those with decreased levels, potentially creating an effective treatment."

Microbial therapy

20 Nov 2023

·www.prnewswire.com

Designs for Health Launches Two Collagen Formulas, Whole Beauty Collagen™ & Collagen + MCT

Leading supplement brand now offers three unique researched-back collagen products PALM COAST, Fla., Nov. 20, 2023 /PRNewswire/ -- Designs for Health, the expert-recommended and preferred brand for high-quality, professional strength, research-backed supplements, and recipient of the 2023 Top Supplement Manufacturing Company award ** today announced the launch of Whole Beauty Collagen™ and Collagen + MCT. These products complement the company's bestselling Whole Body Collagen, now offering consumers three superior, efficacious collagen formulas. Whole Beauty Collagen™ is a convenient once-daily powder featuring hydrolyzed collagen peptides and Lustriva®, a patented, clinically researched blend of stabilized biotin and silica, to provide comprehensive support for hair, skin, and nails.* Evidence suggests that Lustriva® may help promote hair fullness, optimal skin texture, and nail strength.* Additionally, the magnesium biotinate used in this formula may have 40 times greater dissolvability and absorption than the biotin used in common beauty products. Collagen + MCT is a keto-friendly powder featuring hydrolyzed collagen peptides from grass-fed, pasture-raised bovine sources and medium-chain triglycerides (C8 & C10 MCTs) from highly refined coconut oil. MCTs metabolize differently than other fats; the body converts them into ketones, even when not on a ketogenic diet, and provide a quick source of energy that most cells and tissues can use. They are especially known for fueling the brain, heart, and skeletal muscles. Research also suggests that MCTs may provide fuel for brain cells, helping to support cognitive function and mental clarity.* Whole Body Collagen is a synergistic formulation designed to benefit the health of bones, joints, and skin.* It contains the research-backed collagen peptide blends Verisol®, Fortigel®, and Fortibone® derived from specific dietary collagen proteins and produced with proprietary hydrolyzation technologies to optimize their beneficial properties. This unique blend is supported by clinical research showing its efficacy for collagen production, bone strength, joint health and integrity, and skin elasticity.* "While the market for collagen supplements has skyrocketed in recent years, all collagen products are not created equal, which is why we are proud to offer three high-quality research-backed formulations that consumers and practitioners can trust," said Chief Medical Officer, Dr. David M. Brady at Designs for Health. "Collagen makes up roughly 30% of the body's protein and 75% of the skin's structure; however, we start to produce less of it as we age, making supplementation vital to helping the body rebuild the collagen that it depends on. Our three unique SKUs have been carefully formulated to provide adults with an easy and convenient way to incorporate specific molecular weight clinically studied collagen into their daily wellness routines at any age." Designs for Health began in 1989 as a small educational services company with deep roots in natural medicine – and big ambitions to revolutionize the industry. More than 30 years later, the company is pioneering new approaches to nutritional science, breaking barriers in quality standards, and ultimately transforming the healthcare ecosystem. Through a robust product pipeline and a diverse portfolio of more than 300 nutritional products, Designs for Health is leading the charge in the natural and integrative medicine movement to design a well world for all. Whole Beauty Collagen, Collagen + MCT, and Whole Body Collagen are unflavored and unsweetened, making them easy to add to any beverage or shake. They are gluten-free, dairy-free, soy-free, and non-GMO, and available to purchase at . To learn more about Designs for Health and its comprehensive portfolio of products, including its line of oral health products, visit . Please tune in to Designs for Health's new podcast, Conversations for Health, and immerse yourself in the current landscape of Functional Medicine to empower you to design a well world with us. About Designs for Health, Inc. Family-owned Designs for Health, Inc. offers high-quality dietary supplements and functional foods to healthcare professionals and their patients. Guided by its founding philosophy of "Science-First™," the company holds an unwavering commitment to creating research-driven formulations with meaningful quantities of functional ingredients that maximize the potential for successful health outcomes. For over 30 years, Designs for Health has been many healthcare professionals' trusted source for not only product innovation but also leadership in clinical education and practice development solutions. **Awarded by Food Business Review *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Contact: 5WPR 212-999-5585 [email protected] SOURCE Designs for Health

09 Nov 2023

·www.prnewswire.com

LEADING WOMEN'S WELLNESS BRAND O POSITIV ANNOUNCES THE LAUNCH OF WILLO HAIR GROWTH SUPPORT CAPSULES

Supplements Support Healthy Hair Growth and Thicker, Fuller Hair LOS ANGELES, Nov. 9, 2023 /PRNewswire/ -- O Positiv, the supplement brand breaking taboos in women's health, introduces their newest product WILLO Hair Growth Support Capsules . Continue Reading Willo Hair Growth Supplements from O Positiv O Positiv has been at the forefront of women's health since the successful launch of their debut product in 2018, FLO, the first-ever PMS support supplement on the market. The brand's mission is to prioritize and advocate for women's health, by providing effective solutions for health concerns that have been historically overlooked. With an extensive product range dedicated to addressing issues related to vaginal, digestive, urinary, menstrual and menopausal health, O Positiv has firmly established itself as a premier women's health advocate and supporter. WILLO Hair Growth Support Capsules represent O Positiv's dedication to addressing another common yet often unspoken issue for women– thinning hair. These cruelty free, vegan and gluten free supplements are designed to support healthy hair growth, enhance hair follicle health, and help manage the effects of stress on hair. The star ingredient in WILLO Hair Growth Support Capsules is Lustriva®, a patented and clinically-studied complex of biotin, arginine, and silicon known for its superior absorption into the body. Clinical studies have proven its effectiveness in supporting healthy hair growth and promoting thicker, fuller hair. "We're constantly hearing from our customers about the effect of hormonal changes on their hair growth," Co-Founder Brianna Bitton said, "We're overwhelmed by the stories of hair thinning or shedding without an effective or safe-to-take daily product. We're proud to launch WILLO to address these under-discussed issues." Thinning hair is a common concern among women, often associated with various conditions such as hormonal changes due to pregnancy, childbirth, menopause, and thyroid issues, according to the Mayo Clinic. WILLO Hair Growth Supplements aim to empower women with a solution that addresses this challenge they face throughout every stage of life. Each WILLO Hair Growth Support Capsules not only contain Lustriva® but also a variety of other vital ingredients. These include Saw Palmetto, a key ingredient that's been shown to help manage the body's levels of DHT (a hormone known to cause hair follicles to shrink), contributing to healthy follicles; Holy Basil, an adaptogen traditionally used to support healthy stress management; Vitamins E & C, well-researched antioxidants that combat oxidative stress in the body and scalp, supporting hair follicle health; and Hair & Scalp Nutrients, a blend of vitamins and minerals that help fill nutrient deficiencies that may cause thinning / brittle hair (includes selenium, iron, vitamins D3 & B12, folate and zinc). In a clinical study using an ingredient found in WILLO Hair Growth Support Capsules, women saw significant improvement in hair thickness in just 3 weeks, when taken daily. O Positiv plans to continue expanding their range of products, which currently includes favorites - FLO PMS Gummies & Capsules, GOGO Prebiotic Fiber Gummies, URO Urinary Tract & URO Vaginal Probiotic Capsules, GOGO Bloating and Gas Capsules, MENO Menopause Gummies & Capsules and RETRO Glowing Skin Gummies & Capsules. To further advocate for women's health, O Positiv works with the global nonprofit Period to end period poverty and stigma through service, education and advocacy. WILLO Hair Growth Support Capsules retail for $69.99 one time, $59.99 for a subscription at opositiv.com and amazon.com. Follow O Positiv on Instagram at @opositiv. About O Positiv O Positiv is the health and wellness brand prioritizing women by creating effective products to address health concerns that have been historically overlooked. O Positiv aims to break taboos with a line of products to address vaginal, skin, digestive, menstrual and menopausal health. For more information, visit opositiv.com. Press Contact: Shauna Aminzadeh/Break Point [email protected] SOURCE O Positiv

Clinical Result

100 Deals associated with Biotin

External Link

KEGG	Wiki	ATC	Drug Bank
D00029	Biotin	A11HA05	DB00121

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	-	-	-
Eczema	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis	NDA/BLA	EU	MedDay Pharmaceuticals SAS	-
Adrenoleukodystrophy	Phase 3	FR	MedDay Pharmaceuticals SAS	01 Oct 2014
Adrenoleukodystrophy	Phase 3	DE	MedDay Pharmaceuticals SAS	01 Oct 2014
Adrenoleukodystrophy	Phase 3	ES	MedDay Pharmaceuticals SAS	01 Oct 2014
Multiple Sclerosis, Chronic Progressive	Phase 3	FR	MedDay Pharmaceuticals SAS	01 Oct 2013
Optic Neuritis	Phase 3	FR	MedDay Pharmaceuticals SAS	01 Oct 2013
Optic Neuritis	Phase 3	GB	MedDay Pharmaceuticals SAS	01 Oct 2013
Vision, Low	Phase 3	FR	MedDay Pharmaceuticals SAS	01 Oct 2013
Vision, Low	Phase 3	GB	MedDay Pharmaceuticals SAS	01 Oct 2013
Charcot-Marie-Tooth Disease, Type Ia	Phase 2	FR	MedDay Pharmaceuticals SAS	05 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ENDO2024	Not Applicable	Hyperandrogenism	-	Biotin	pfhbmieltc(zwpmgypsah) = kkbrdirlol mbcfxmcaqc (puwwuxjgwl ) View more	-	01 Jun 2024
EADV2023	Not Applicable	-	61	Oral biotin	uwyvjurrnb(pwyrofriwv) = eehuhkrtiu eqcssifbje (hsgkfkzqkw ) View more	Positive	11 Oct 2023
EADV2023	Not Applicable	-	61	Pyridoxine	uwyvjurrnb(pwyrofriwv) = dgbycgdrlu eqcssifbje (hsgkfkzqkw ) View more	Positive	11 Oct 2023
SSIEM2023	Not Applicable	Congenital Disorders of Glycosylation biotinidase activity	29	biotin	yajbgyshid(zivrmzkbao) = lxivtqzbpt zgbhjqwhhu (ksdjiwnmsy )	-	30 Aug 2023
NCT02757898 (b-RBCs, CTgov)	Phase 1	Anemia	5	Biotin-Labeled Red Blood Cells (RBCs)	zyxqwfmmua(ptzjbwcznq) = aqnqhnkpek odyjrijnoa (scvlzfylsh, mhrykjgbdz - auispoljbh) View more	-	09 May 2023
PMON224 (ENDO2022)	Not Applicable	postmenopausal disorder	-	Biotin	jynvtrrocs(mmnivviarp) = nzajlmckxo pkogfzxomx (yqlqpatkzl )	-	01 Nov 2022
AAN2022	Not Applicable	Multiple Sclerosis	889	High-dose biotin (HDB)	yozorwtwlr(wpzkaiiitf) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference rcdgjrewlh (dloduouxen )	-	03 May 2022
AAI2022	Not Applicable	-	-	Biotin (SLC5A6 mutations)	fnrccyfejk(sesqgcabow) = jdbutnhqvf fvyjoyvcbj (swceemifcs ) View more	-	01 May 2022
AAI2022	Not Applicable	-	-	Biotin replenishment	fnrccyfejk(sesqgcabow) = vhddwhzgzf fvyjoyvcbj (swceemifcs ) View more	-	01 May 2022
ENDO2021	Not Applicable	Adrenal Insufficiency ACTH \| morning cortisol \| DHEA-S	-	Hydrocortisone therapy	dzwrbassic(btoccqqkpu) = qhhwhyxnsx bitryrjine (fcwzlqaqkj, 7.2–63.3)	-	03 May 2021
NCT02936037 (SPI2, Pubmed) Manual	Phase 3	Multiple Sclerosis, Chronic Progressive	642	MD1003	kqluroakhr(ockduupeiw) = ixibpplvnw wsjxebwcvm (quevbqflrz ) View more	Negative	01 Dec 2020
NCT02936037 (SPI2, Pubmed) Manual	Phase 3	Multiple Sclerosis, Chronic Progressive	642	Placebo	kqluroakhr(ockduupeiw) = iepiyipfaq wsjxebwcvm (quevbqflrz ) View more	Negative	01 Dec 2020
NCT02936037 (SPI2, CTgov)	Phase 3	Multiple Sclerosis, Chronic Progressive	642	PLACEBO (GROUP 1)	apybcxakwh(jonfmkuipw) = ilwlmrwkkz hsedjdpgxj (bbqlrxonee, fbopmdbemu - pmgafrvojr) View more	-	23 Nov 2020
NCT02936037 (SPI2, CTgov)	Phase 3	Multiple Sclerosis, Chronic Progressive	642	MD1003 100mg capsule (GROUP 2)	apybcxakwh(jonfmkuipw) = ijuuunlpks hsedjdpgxj (bbqlrxonee, hbevocwbwn - eqfsjhtjcq) View more	-	23 Nov 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Biotin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation